Growth Metrics

Jazz Pharmaceuticals (JAZZ) Long-Term Debt Repayments (2020 - 2021)

Jazz Pharmaceuticals has reported Long-Term Debt Repayments over the past 2 years, most recently at $218.8 million for Q3 2021.

  • Quarterly Long-Term Debt Repayments rose 839.11% to $218.8 million in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $218.8 million through Dec 2023, changed 0.0% year-over-year, with the annual reading at $575.0 million for FY2024, N/A changed from the prior year.
  • Long-Term Debt Repayments was $218.8 million for Q3 2021 at Jazz Pharmaceuticals, up from $23.3 million in the prior quarter.
  • Over five years, Long-Term Debt Repayments peaked at $218.8 million in Q3 2021 and troughed at $23.3 million in Q3 2020.